Adamis Receives FDA Approval for ZIMHI
18 oct. 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone...
Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors
04 oct. 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the company’s...
Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19
02 sept. 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral...
Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other Events
24 août 2021 16h05 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that David C. Benedicto, who has been serving as the Company’s Chief Accounting...
Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patient’s Cells
24 août 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
Tempol: A potential home treatment for COVID-19 (https://covid19.nih.gov/news-and-stories/tempol-potential-home-treatment-covid-19). Trial to begin shortly. SAN DIEGO, Aug. 24, 2021 (GLOBE...
Adamis Highlights National Institutes of Health (NIH) Article Entitled, “Tempol: A Potential Home Treatment for COVID-19”
19 août 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today highlighted that the NIH has identified Tempol as a potential home treatment for COVID-19...